Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

South Korea-based Hanmi Pharmaceutical has reported positive outcomes from a Phase I/II clinical trial of Tivumecirnon ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

China has become the second-largest developer of new drugs, behind only America. Read more at straitstimes.com.